Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Novartis has a collaboration agreement with ... With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains.

Novartis (NVS) reported $13.15 billion in revenue ... With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains.

Since 2021, there’s been an increase in representation of people from underrepresented and underserved communities in Super ...

As you saw this morning, Novartis delivered one of the strongest ... that's a good starting base. And also our other products are quite profitable. Now, of course, profitability does vary by ...

The Super Bowl has always been more than a game—it’s a cultural barometer, reflecting how brands engage with audiences at the ...

As HR's strategic role evolves, people professionals must leverage tech alongside human skills to drive success, says BVI ...

Novartis has moved a step closer to EU approval ... The optional sensor attaches to the base of the Breezhaler device and collects data on the use of the inhaler, sending data remotely to an ...